Specific genetic polymorphisms in IL-1β and TNF-α genes may elevate PD risk [81], and metformin’s ability to reduce these pro-inflammatory cytokines could make it especially beneficial for PD patients with these specific gene variations [81]. This evidence concerns the gene IL1B and Parkinson disease.